cover story
NO MORE A HOT DESTINATION:
WILL INDIA CREATE A ROADMAP FOR ITS
CLINICAL RESEARCH INDUSTRY?
There used to be a time when
India was an instant hit globally for
its affordable yet quality expertize
in handling clinical trials but then
home grown scaremongering
demonized this industry, leading
to the obvious loss of fortunes.
Here we analyse the ups and
downs of past, present
opportunities and challenges
besides what lies ahead for it
14
BioVoiceNews | July 2016
W
BY RAHUL KOUL
ith over 16 percent of global population
living in India, the country shares 20
percent of the world’s disease burden. The
growing number of patients who spend out of pocket
money for healthcare will require affordable
medicine at par with their food and living
requirements. In steep contrast to that, it is equally
surprising to note that we contribute only 1.4
percent in terms of clinical trials to the drug
development process worldwide. Infact, the last few
years witnessed huge setback to clinical research
scenario in India as the number of actual approvals
declined significantly. From booming industry in